 PRINCETON, N.J., June 03, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced the expansion of its pipeline with the introduction of Enriched Tear Film ETFTM Gene Therapy and proof-of-concept in vivo study results from its first gene therapy candidate, OC-101. 